CHT, HeiQ partner to produce antiviral treatment for textiles
Posted June 25, 2020
TÜBINGEN, Germany – CHT is cooperating with HeiQ by globally implementing the HeiQ Viroblock by CHT in the textile industry.
Ralf Kattanek, vice president of Textiles of CHT Group, underlined a statement by Carlo Centonze, Swiss co-founder and CEOof HeiQ Group: “The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone. This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic.”
HeiQ Viroblock by CHT is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory. Tests have been conducted by the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia showed that treated fabric achieved 99.99 percent reduction of the virus.
HeiQ Viroblock by CHT is a textile treatment for industrial use, designed to provide textiles with antiviral and antibacterial properties. The combination of silver antimicrobial technology and vesicle technology rapidly destroys enveloped viruses, including coronaviruses, CHT said. It has previously been tested against coronavirus 229E, another strain of virus in the Coronavirus family.
The latest testing with SARS-CoV-2 virus was conducted by researchers at the Doherty Institute, a joint venture between the University of Melbourne and The Royal Melbourne Hospital, an internationally renowned institution combining research, teaching, public health and reference laboratory services, diagnostic services and clinical care into infectious diseases and immunity. The research project involved a disinfection test protocol that simulated the real-life interaction of small aerosol droplets contaminating clothing.
A known concentration of SARS-CoV-2 virus was contacted with the sample fabric for 30 minutes followed by measurement of remaining infectious SARS-CoV-2 viruses. The fabric sample treated with HeiQ Viroblock by CHT had no infective viruses left after 30 minutes. The result indicated a SARS-CoV-2 virus reduction of 99.99 percent relative to the inoculum control.
“A key part of the Institute’s current COVID-19 research focus is on testing different ways to achieve an antiviral effect against the SARS-CoV-2 virus,” said Dr. Julie McAuley, senior research officer at the Doherty Institute. “Testing the action of different disinfectants and surface treatments is one way that our research can help provide insights towards helping to stop the pandemic.”
“We are very happy that the test by the Doherty Institute proved the effectiveness against the SARS-CoV-2 virus,” Kattanek said. “The test result will support our efforts to put the HeiQ Viroblock by CHT into protective textile applications. This antiviral treatment can play a key role for medical protective equipment, but above all in the area of workwear, home textiles and technical textiles. Together with our partners from the textile industry as well as the brands and retailers, we have started the fight against the global pandemic.”
Source: CHT Group